CY2481B1 - Antifungal combination therapy. - Google Patents

Antifungal combination therapy.

Info

Publication number
CY2481B1
CY2481B1 CY0400076A CY0400076A CY2481B1 CY 2481 B1 CY2481 B1 CY 2481B1 CY 0400076 A CY0400076 A CY 0400076A CY 0400076 A CY0400076 A CY 0400076A CY 2481 B1 CY2481 B1 CY 2481B1
Authority
CY
Cyprus
Prior art keywords
antifungal
inhibitors
combination therapy
combination
xmp
Prior art date
Application number
CY0400076A
Other languages
English (en)
Inventor
Kenneth F Bartizal
George K Abruzzo
Amy M Flattery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9620739.4A external-priority patent/GB9620739D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY2481B1 publication Critical patent/CY2481B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0400076A 1996-09-12 2004-10-27 Antifungal combination therapy. CY2481B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2632796P 1996-09-12 1996-09-12
GBGB9620739.4A GB9620739D0 (en) 1996-10-04 1996-10-04 Antifungal combination therapy

Publications (1)

Publication Number Publication Date
CY2481B1 true CY2481B1 (en) 2005-06-03

Family

ID=26310166

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400076A CY2481B1 (en) 1996-09-12 2004-10-27 Antifungal combination therapy.

Country Status (21)

Country Link
EP (1) EP0925070B1 (fr)
JP (1) JP3288051B2 (fr)
KR (1) KR100380871B1 (fr)
CN (1) CN1235554A (fr)
AT (1) ATE248625T1 (fr)
AU (1) AU721334B2 (fr)
CA (1) CA2265824C (fr)
CY (1) CY2481B1 (fr)
CZ (1) CZ88499A3 (fr)
DE (1) DE69724626T2 (fr)
DK (1) DK0925070T3 (fr)
EA (1) EA002469B1 (fr)
EE (1) EE03748B1 (fr)
ES (1) ES2203819T3 (fr)
IL (1) IL128870A0 (fr)
NO (1) NO991207L (fr)
NZ (1) NZ334446A (fr)
PL (1) PL333282A1 (fr)
PT (1) PT925070E (fr)
SK (1) SK29999A3 (fr)
WO (1) WO1998010782A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753001B1 (fr) * 1994-11-08 1999-09-08 Glaxo Wellcome S.A. Derives de sordaridine a action antifongique
US6069126A (en) * 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
KR100680464B1 (ko) * 2000-06-28 2007-02-08 주식회사 하이닉스반도체 반도체 소자의 캐패시터 제조 방법
WO2002098463A1 (fr) * 2001-06-05 2002-12-12 The New Industry Research Organization Compositions antifongiques
PL1867332T3 (pl) 2005-04-07 2012-01-31 Toyama Chemical Co Ltd Kompozycja farmaceutyczna i sposób sterowania środka przeciwgrzybiczego w kombinacji
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
CA2664915C (fr) 2006-10-06 2014-01-07 Toyoma Chemical Co., Ltd. Composition pharmaceutique contenant un derive de phenylamidine et procede d'utilisation de la composition pharmaceutique combinee a un agent antifongique
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20110076240A1 (en) * 2008-04-18 2011-03-31 Day Donal F Antifungal and Anti-Cariogenic Cellobio-Oligosaccharides Produced by Dextransucrase
CN102274217B (zh) * 2010-06-10 2013-04-10 吉林大学 三氯生作为抗真菌药物氟康唑增效剂的新用途
CN102274216B (zh) * 2010-06-10 2013-04-10 吉林大学 一种提高氟康唑抗真菌作用的增效剂
CN102274215B (zh) * 2010-06-10 2013-04-10 吉林大学 一种具有与氟康唑协同抗真菌作用的增效剂
US20130288956A1 (en) 2010-11-05 2013-10-31 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
US8623813B2 (en) * 2011-05-24 2014-01-07 Bayer Cropscience Lp Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use
CN102319326A (zh) * 2011-07-23 2012-01-18 李玮 一种治疗脚癣的浸药卫生纸
CN114652836B (zh) * 2022-03-25 2023-06-20 山东大学 T3ss小分子抑制剂及其筛选方法和应用
CN116473985A (zh) * 2023-03-29 2023-07-25 暨南大学 一种多烯类抗真菌药物组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds

Also Published As

Publication number Publication date
NO991207D0 (no) 1999-03-11
IL128870A0 (en) 2000-06-01
KR100380871B1 (ko) 2003-04-18
ES2203819T3 (es) 2004-04-16
EE03748B1 (et) 2002-06-17
EA199900283A1 (ru) 1999-08-26
NO991207L (no) 1999-05-11
CA2265824C (fr) 2004-11-09
NZ334446A (en) 2000-11-24
CZ88499A3 (cs) 1999-10-13
ATE248625T1 (de) 2003-09-15
SK29999A3 (en) 2000-02-14
JP3288051B2 (ja) 2002-06-04
AU721334B2 (en) 2000-06-29
EA002469B1 (ru) 2002-06-27
DE69724626T2 (de) 2004-07-29
WO1998010782A1 (fr) 1998-03-19
EP0925070B1 (fr) 2003-09-03
PT925070E (pt) 2003-12-31
AU4339297A (en) 1998-04-02
DK0925070T3 (da) 2003-12-01
KR20000036054A (ko) 2000-06-26
CN1235554A (zh) 1999-11-17
CA2265824A1 (fr) 1998-03-19
PL333282A1 (en) 1999-11-22
EE9900088A (et) 1999-10-15
DE69724626D1 (de) 2003-10-09
EP0925070A1 (fr) 1999-06-30
JP2000503675A (ja) 2000-03-28

Similar Documents

Publication Publication Date Title
CY2481B1 (en) Antifungal combination therapy.
Rousey et al. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation
Galgiani Fluconazole, a new antifungal agent
WO2000072865A3 (fr) Utilisation combinee d'antifongiques
GB2380126B (en) Improvements in and relating to adjustable chairs and beds
Clark et al. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C
US6069126A (en) Antifungal combination therapy
Meletiadis et al. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans
Macura The Influence of Some Antifungal Drugs on In Vitro Adherence of Candida albicans to Human Buccal Epithelial Cells: Der Einfluß einiger Antimyzetika auf die Adhärenz von Candida albicans in vitro an Epithelzellen der Mundschleimhaut des Menschen
Deacon et al. The effect of nitrous oxide-induced inactivation of vitamin B12 on thymidylate synthetase activity of rat bone marrow cells
IT1297538B1 (it) Enteroclisma di lattulosio/lattitolo con o senza aggiunta di neomicina per la cura della encefalopatia portosistemica acuta
Calandra et al. Response to van Saene et al.'s comment on" Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients"
FI944017A0 (fi) Makrolidien sokerijohdannaiset
陆寿康 Acupuncture treatment of soft tissue injury
UCHIDA et al. Studies on the Antifungal Activities of 5-Flurocytosine 4. In Vitro and In Vivo Antitungal Activities against Dematiaceous Fungi
陈国宁 Too Much Sex Can Bring Footballers to their Knees
AU3698099A (en) Compostable orthopedic curative and auxiliary agent, especially in the form of cushions
AU9530101A (en) Medicinal composition and in particular its use in fluid therapy
IT1312003B1 (it) Uso di lonidamina e suoi derivati nel trattamento di affezioni causateda retrovirus.